Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Polpharma Biologics
Advertisement
Polpharma Biologics Secures FDA and EMA Review for PB016
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
Teva Expands Global Biosimilar Portfolio With Polpharma
TEL AVIV, Israel / ZUG, Switzerland | July 9, 2026 Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical...
Polpharma Biologics and Tuteur Sign LATAM Autoimmune Biosimilar Deal
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
Advertisement
